Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Ondersteunde ambulatie om de gezondheidsresultaten voor oudere medische patiënten te verbeteren

4 november 2026 bijgewerkt door: Michael Rothberg, The Cleveland Clinic

Gerandomiseerde proef van geassisteerde ambulatie om de gezondheidsresultaten voor oudere medische patiënten te verbeteren

The investigator proposes to conduct a randomized trial of supervised ambulation delivered by mobility technician (MT) up to three times daily, including weekends, to hospitalized medical patients. The aims of the study are to compare the short and intermediate-term outcomes of patients randomized to the intervention versus those patients randomized to receive usual care, to identify patients who are most likely to benefit from the intervention and to assess whether the intervention increases or decreases overall costs of an episode of care, including the cost of the MTs, the index hospitalization and the first 30 days post enrollment.

Studie Overzicht

Gedetailleerde beschrijving

The investigator proposes to conduct a large randomized trial to test the impact of MTs (Mobility Technicians) on short and intermediate term outcomes for 3000 patients aged 65 years and older at 5 hospitals in 2 health systems. Patients will be randomized to receive supervised ambulation up to 3 times daily with a MT or to receive usual care. All participants will wear an accelerometer on their wrist to track their movement throughout the hospital stay. The study has 3 aims. First, the study will compare the mobility of patients at discharge (or 10 days) to assess the impact of the MTs on this outcome. Of particular interest is whether the use of MTs will increase the proportion of patients who can go home vs.post-acute care, and whether the improvements in mobility are sustained at 30 days. Second, the study will use predictive modeling to identify which patients are most likely to benefit from this intervention. Third, the study will assess the impact of the intervention on overall costs associated with the episode of care, including inpatient costs and the 30 days post enrollment. This information will be important to convince health systems to adopt this approach.

Studietype

Ingrijpend

Inschrijving (Geschat)

3000

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Michael Rothberg, M.D.
  • Telefoonnummer: 216-445-0719
  • E-mail: rothbem@ccf.org

Studie Locaties

    • Massachusetts
      • Springfield, Massachusetts, Verenigde Staten, 01199
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44111
        • Werving
        • Fairview Hospital
        • Contact:
          • Michael Rothberg, MD
          • Telefoonnummer: 216-445-0719
          • E-mail: rothbem@ccf.org
      • Cleveland, Ohio, Verenigde Staten, 44195
        • Werving
        • Cleveland Clinic- Main Campus
        • Contact:
          • Michael Rothberg, MD
          • Telefoonnummer: 216-445-0719
          • E-mail: rothbem@ccf.org
      • Garfield Heights, Ohio, Verenigde Staten, 44125
        • Beëindigd
        • Marymount Hospital
      • Mayfield Heights, Ohio, Verenigde Staten, 44124
        • Werving
        • Hillcrest Hospital
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

65 jaar en ouder (Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Participants must meet all of the inclusion criteria listed below to participate in this study:

  1. ≥65 years of age
  2. Admitted to a medical service
  3. Complete history and physical examination on file
  4. 6-Clicks score of 16-23
  5. Insurance with Traditional Medicare or Medicare Advantage

Exclusion Criteria:

Any patient meeting any of the exclusion criteria listed below at baseline will be excluded from study participation:

  1. Significant language barrier that requires a translator (other than Spanish at Baystate site only)
  2. Discharge planned for that day or the following day
  3. Observation status
  4. Surgical procedure planned
  5. Patients diagnosed with unstable angina or other medical conditions precluding participation in exercise/ambulation
  6. Permanent residence in a skilled nursing facility
  7. Comfort care measures only
  8. >48 hours since admission
  9. Active infection with COVID-19
  10. Other active infection requiring contact or droplet precautions
  11. Order for bedrest

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Geen tussenkomst: Usual Care

No intervention

Experimenteel: Mobility Technician

Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session

Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Short Physical Performance Battery (SPPB) from admission
Tijdsspanne: Up to 10 days

Every patient will have an SPPB score on admission to the study. A blinded assessor will measure the SPPB again at discharge or on day 10 if the patient is still hospitalized. The primary outcome is change from admission to discharge. Investigators will also compare the percentage of patients who reach the minimal clinically important difference of 1 point.

SPPB minimum value= 0 SPPB maximum value= 12 (higher score indicates a better outcome). If no blinded team member is available, the evaluation may be carried out by any unblinded team member. The blinding status of the evaluator will be noted in REDCap.

Up to 10 days

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Patient-Reported Outcomes Measurement Information System (PROMIS) physical function - mobility
Tijdsspanne: 30 days post enrollment

Patients will complete the PROMIS physical function mobility bank via REDCap at 30 days post enrollment. PROMIS allows use of computer-adapted testing to measure patient-reported outcomes. The mobility question bank focuses on activities of physical mobility such as getting out of bed or a chair to walking up stairs. PROMIS measures were developed and validated with state-of-the-science methods supported by National Institutes of Health (NIH) funding. PROMIS was designed to enhance communication between clinicians and patients in diverse research and clinical settings and to be relevant across all conditions for the assessment of symptoms and functions.

PROMIS minimum value= 0 PROMISE maximum value= 100 (higher score indicates a better outcome)

30 days post enrollment
Activity Measure for Post-Acute Care (AM-PAC) basic mobility outpatient short form (SF)
Tijdsspanne: 30 days post enrollment

Subjects will complete the AM-PAC at 30 days post enrollment and the score will be transformed using the t-scale. In addition to comparing AM-PAC scores at 30 days, the investigator will also compare change in t-score from admission. The AM-PAC 6-clicks (assessed in the hospital) and the AM-PAC outpatient SF are normed to the same t-scale, allowing for conversion from the one to the other. The 6-clicks is scored by a clinical proxy, while the SF AM-PAC is self-reported, allowing for initial assessment by the MT and 30-day self-report by the patient. Previous studies have demonstrated adequate validity of mobility assessment via the AM-PAC using clinical or family proxies. To improve interpretability, investigators will compare the percentage of patients who reach the minimal clinically important difference of 3 points on the t-scale.

AM-PAC minimum value= 29.41 AM-PAC maximum value= 80.30 (higher score indicates a better outcome)

30 days post enrollment
Hospital-Acquired Complications
Tijdsspanne: 10 days

Composite outcome of venous thromboembolism, fall with injury, pressure ulcers or hospital-acquired pneumonia. Hospital-acquired complications will be identified from the electronic health record and from the falls reporting system. All falls will be examined, whether occurring during assisted ambulation or otherwise. Only falls with injury will be included in the hospital-acquired complications measure. Outcomes will be adjudicated by blinded reviewers. While investigators are primarily interested in the composite measure, investigators will also examine the individual components separately.

10 days
Number of Patients with Readmission within 30 days
Tijdsspanne: 30 days after discharge

All cause readmission within 30 days of discharge from the index hospitalization.

30 days after discharge
Activities of Daily Living
Tijdsspanne: 30 days post enrollment

Activities of daily living as measured by the Katz and Lawton scales.

Katz minimum value= 0 Katz maximum value= 6 (higher score indicates a better outcome) Lawton minimum value= 0 Lawton maximum value= 8 (higher score indicates a better outcome)

30 days post enrollment
Frailty
Tijdsspanne: 30 days post enrollment

Frailty as measured by the Fatigue, Resistance, Ambulation,Illness, and Loss of weight (FRAIL) scale.

FRAIL minimum value= 0 FRAIL maximum value= 5 (higher score indicates a worse outcome)

30 days post enrollment
Total episode cost
Tijdsspanne: Admission to 30 days post enrollment

Investigators will estimate total cost of the episode of care including the index admission (from hospital cost accounting systems), the personnel costs for the MTs (using hourly wages plus benefits), and all non-medication costs for the 30 days post-enrollment (from Medicare claims).

Admission to 30 days post enrollment
Number of Patients Discharged to Home
Tijdsspanne: date of randomization to date of discharge, up to 30 days

Based on the discharge disposition in the medical record, investigators will identify whether the patient was discharged to home.

date of randomization to date of discharge, up to 30 days
Length of Stay
Tijdsspanne: date of admission to date of discharge, up to 30 days

Length of stay will be calculated as whole days from the time of admission to the time of discharge.

date of admission to date of discharge, up to 30 days
Mortality
Tijdsspanne: 30 days from admission

Patient's vital status will be ascertained from the EHR, Medicare claims or from follow-up phone calls.

30 days from admission
Total episode cost
Tijdsspanne: Admission to 6 months after enrollment

Investigators will estimate total cost of the episode of care including the index admission (from hospital cost accounting systems), the personnel costs for the MTs (using hourly wages plus benefits), and all non-medication costs for the 6 months post-enrollment (from Medicare claims).

Admission to 6 months after enrollment
Falls post-discharge
Tijdsspanne: 30 days from admission

Whether the patient has fallen, whether it was multiple times and whether an injury occurred will be assessed via telephone

30 days from admission
RCSQ (Richards Campbell Sleep Questionnaire)
Tijdsspanne: Days 1-10

Five question sleep survey which measures overall quality of sleep. Patients in both study arms will complete the questionnaire each morning regarding the previous night's sleep.

Days 1-10

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Michael Rothberg, M.D., The Cleveland Clinic

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 mei 2023

Primaire voltooiing (Geschat)

30 november 2026

Studie voltooiing (Geschat)

30 december 2026

Studieregistratiedata

Eerst ingediend

11 januari 2023

Eerst ingediend dat voldeed aan de QC-criteria

10 februari 2023

Eerst geplaatst (Werkelijk)

13 februari 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren